{
    "clinical_study": {
        "@rank": "131254", 
        "acronym": "SBI for COPD", 
        "arm_group": [
            {
                "arm_group_label": "inactive powder substance", 
                "arm_group_type": "Placebo Comparator", 
                "description": "inactive powder substance by mouth twice a day for 6 months"
            }, 
            {
                "arm_group_label": "serum bovine immunoglobulin (SBI) medical food", 
                "arm_group_type": "Experimental", 
                "description": "SBI medical food 5 gr powder substance by mouth twice a day for 6 months"
            }, 
            {
                "arm_group_label": "serum bovine immunoglobulin (SBI) medicalfood", 
                "arm_group_type": "Experimental", 
                "description": "SBI medical food 10 gr powder substance by mouth twice a day for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the use of a medical food, oral serum-derived bovine\n      immunoglobulin/protein isolate (SBI), in helping patients with advanced COPD with cachexia\n      (a wasting syndrome) improve their nutritional status and gain weight. The medical food is\n      in powder form and is mixed with a liquid such as water or orange juice and consumed by\n      swallowing. The primary hypothesis is that SBI protein isolate (SBI) will improve the\n      nutritional status of cachexic patients with advanced stages of COPD."
        }, 
        "brief_title": "Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Advanced COPD", 
        "condition": "Advanced COPD (GOLD Stage 3 or 4) With Cachexia", 
        "condition_browse": {
            "mesh_term": [
                "Cachexia", 
                "Pulmonary Disease, Chronic Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between age 30 and 80 at Baseline Visit\n\n          -  Diagnosed with 2012 spirometric COPD GOLD Stage 3 (FEV1/FVC ratio <0.70, FEV1 30-49%\n             of normal) or GOLD Stage 4 (FEV1/FVC <0.70, FEV1 <30% of normal or FEV1<50% of normal\n             with chronic respiratory failure present)\n\n          -  Able to tolerate and willing to undergo study procedures\n\n          -  Body Mass Index below 21\n\n          -  Signed Informed Consent\n\n        Exclusion Criteria:\n\n          -  History of comorbid condition severe enough to significantly impact 6 months outcomes\n\n          -  Current substance abuse, including tobacco, alcohol and illicit drugs\n\n          -  Diagnosis of unstable cardiovascular disease including myocardial infarction in the\n             past 6 weeks, uncontrolled congestive heart failure, or uncontrolled arrhythmia\n\n          -  Dementia or other cognitive dysfunction which in the opinion of the investigator\n             would prevent the participant from consenting to the study or completing study\n             procedures\n\n          -  Active pulmonary infection with tuberculosis\n\n          -  Non-COPD obstructive lung disease (various bronchiolitides, sarcoidosis, LAM,\n             histiocytosis X) or parenchymal lung disease, pulmonary vascular disease, pleural\n             disease, severe kyphoscoliosis, neuromuscular weakness, or other cardiovascular and\n             pulmonary disease, that limit the interpretability of the pulmonary function measures\n\n          -  Prior significant difficulties with pulmonary function testing\n\n          -  Hypersensitivity to or intolerance of albuterol sulfate or ipratropium bromide or\n             propellants or excipients of the inhalers, or to beef\n\n          -  History of lung or other organ transplant\n\n          -  Currently taking >20mg of prednisone or equivalent systemic corticosteroid\n\n          -  Currently taking any immunosuppressive agent\n\n          -  History of lung cancer or any cancer that spread to multiple locations in the body\n\n          -  Known HIV/AIDS infection\n\n          -  History of or current exposure to chemotherapy or radiation treatments that, in the\n             opinion of the investigator, limits the interpretability of the pulmonary function\n             measures.\n\n          -  Current or planned pregnancy within the study course.\n\n          -  Currently institutionalized (e.g., prisons, long-term care facilities)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02067377", 
            "org_study_id": "000027289"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "serum bovine immunoglobulin (SBI) medical food", 
                    "serum bovine immunoglobulin (SBI) medicalfood"
                ], 
                "description": "Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.", 
                "intervention_name": "Serum bovine immunoglobulin (SBI) medical food", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "inactive powder substance", 
                "intervention_name": "Placebo (for serum bovine immunoglobulin)", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulins", 
                "Antibodies"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "GOLD, COPD, cachexia, BMI", 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "eways@musc.edu", 
                "last_name": "Kalon Eways, BS", 
                "phone": "843-792-6696"
            }, 
            "contact_backup": {
                "email": "lucap@musc.edu", 
                "last_name": "Luca Paoletti, MD", 
                "phone": "843-792-3712"
            }, 
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29425"
                }, 
                "name": "Medical University of South Carolina"
            }, 
            "investigator": {
                "last_name": "Luca Paolettic, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double Blinded, Placebo-controlled Pilot Study of Serum Bovine Immunoglobulin (SBI) for Cachexia in Patients With Advanced COPD", 
        "other_outcome": [
            {
                "measure": "The subtracted differences in swallowing-associated laryngeal Penetration Aspiration Scale (PAS) in patients receiving SBI or placebo at baseline and 6 months.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "The subtracted differences in mean serum TNF-alpha and IL-6 concentrations between participants receiving SBI or placebo at baseline and 6 months.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "overall_contact": {
            "email": "eways@musc.edu", 
            "last_name": "Kalon Eways, BS", 
            "phone": "843-792-6696"
        }, 
        "overall_contact_backup": {
            "email": "lucap@musc.edu", 
            "last_name": "Luca Paoletti, MD", 
            "phone": "843-792-3712"
        }, 
        "overall_official": [
            {
                "affiliation": "MUSC", 
                "last_name": "Luca Paoletti, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "MUSC", 
                "last_name": "Kalon Eways, BS", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "MUSC", 
                "last_name": "Mary Brooks, BS", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The subtracted differences in BMI, body fat measurement, and grip strength between participants receiving SBI or placebo at baseline and 6 months.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02067377"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The subtracted differences between FEV1 and COPD Assessment Test scores in patients receiving SBI or placebo at baseline and 6 months.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "collaborator": {
                "agency": "Entera Health", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}